Overall use of a web-based tool providing real-time, personalized episode-level price estimates for healthcare was low, but for some procedures the number of people searching for prices of services was high relative to the number of people who received the service.
Overall use among nonelderly insured adults of a web-based tool providing real-time, personalized episode-level price estimates for healthcare was low, but for some procedures the number of people searching for prices of services was high relative to the number of people who received the service, according to a study in Health Affairs.
In addition, the study found that Aetna’s Member Payment Estimate price transparency tool was more likely to be used by patients who were researching imaging, childbirth, or one of several outpatient procedures and who were significantly more likely to be younger and healthier and to have incurred a higher annual deductible spending than patients who did not search for price information.
Study authors Anna D. Sinaiko, PhD, and Meredith B. Rosenthal, PhD, both of the Harvard T.H. Chan School of Public Health, studied Aetna’s Member Payment Estimator, which was launched in 2010. The tool provides real-time, personalized, episode-level estimates of both total prices and a patient’s out-of-pocket expenses at specific providers for over 650 medical services. Aetna considers these services to be those offering the biggest opportunities to save on healthcare expenses and for which consumers were most likely to comparison shop.
The study sample was limited to adults 19 to 64 years of age who were enrolled in Aetna for at least 7 months in 2011-2012. The sample consisted of 616,779 enrollees, of whom 332,255 searched the Estimator tool for price information (“searchers”); 159,909 were randomly selected nonsearchers and 124,615 were enrollees who received a service in 2011-2012 for which price estimates were available on the Estimator but who never used the tool. Results were reported from 2 models: 1 that included 5 services received by women only (mammogram, c-section, vaginal delivery, and gynecologic office visits) and 1 that included the remaining 19 selected services.
In the first full year that the tool was available, 112,372 subscribers (1.6% of those eligible) queried the tool to get a price estimate for themselves at least once. Use increased by 43% in the second year, to 160,307 subscribers (2.4% of all those eligible).The vast majority of subscribers using the Estimator in 2012 were first-time searchers. A total of 3.5% of subscribers used the tool once in 2011-2012. Price estimates were more likely to be for women, and searchers were more likely to be younger or to have a major health condition or comorbidity. They were significantly more likely to have used medical care, compared with nonsearchers.
The study authors said that the rising prevalence of high deductibles in health plans is creating large populations of patients who have financial incentives to choose a low-cost provider. Technologic innovations that can deliver real-time estimated healthcare prices can potentially be a driver of price transparency.
“However, the functionality, comprehensiveness, and usability of these price data vary considerably,” the authors wrote.
For price information to be helpful and usable, it must provide a meaningful estimate of a patient’s total expected costs as opposed to an average unit cost, and not all healthcare services lend themselves to consumer shopping. For healthcare price transparency to become an integral part of patient decision making, the study authors suggest that innovative approaches are needed to engage more consumers to use transparency tools.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More